Medicines of botanical origin for the treatment of addictions

NFL Biosciences develops botanical medicines for the treatment of addictions, with the goal of eventually partnering them with pharmaceutical companies
bt_bb_section_bottom_section_coverage_image

Our latest news

Click the image to hear Yannick Plétan’s message in video form (in French)
https://www.nflbiosciences.com/wp-content/uploads/2020/05/Minia_YP_Cap1-640x640.jpg
https://www.nflbiosciences.com/wp-content/uploads/2020/05/Minia_YP_Cap2-640x640.jpg
https://www.nflbiosciences.com/wp-content/uploads/2020/05/Minia_YP_Cap3-640x640.jpg

Our expertise

Focus on the 3 most common addictive substances, which are frequently present at the same time

Revolutionizing withdrawal treatments

NFL-101 & NFL-102: An innovative drug candidate for smoking cessation derived from a nicotine-free tobacco leaf protein extract

NFL 301: A drug candidate to combat excessive alcohol consumption from a traditional Chinese medicine plant

NFL BIOSCIENCES KEY FIGURES

2021
Initial Public Offering
14
m€ raised on Euronext Growth
3
clinical studies on NFL-101
1
clinical study on NFL-102 in progress

An outsourced scientific research company with low operating costs

PRECLINICAL AND CLINICAL STUDIES
HIGH ENVIRONMENTAL IMPACT APPROACH
SEVERAL SCIENTIFIC AWARDS
GLOBAL SCIENTIFIC EXPERTISE IN BOTANICAL MEDICINES
5 PATENT FAMILIES
MANUFACTURING IN FRANCE AND RESPECT FOR BPF